新型GLP-1/GIP/GCG三重受体激动剂的设计,合成和结构-活性关系研究
Jinhua Zhang1, Hongjiang Xu2, Yuanzhen Dong3
1Shanghai Duomirui Biotechnology Ltd., Shanghai, China; School of Biological Engineering Henan University of Technology, Henan, China.
European journal of medicinal chemistry
|August 1, 2025
概括
针对GLP-1,GIP和GCG的新型三重受体激动剂被开发用于增强血糖控制和减肥. 在临床前的模型中,化合物TRA24在体内表现出高于tirezepatide的疗效.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 药用化学 医学化学
背景情况:
- 肥胖和2型糖尿病需要新的治疗策略.
- 多抗激素疗法有可能改善血糖控制和体重管理.
研究的目的:
- 设计和合成新的葡萄糖样-1 (GLP-1) /依赖葡萄糖的胰岛素变性 (GIP) /葡萄糖 (GCG) 三重受体激动剂.
- 评估这些新型化合物的体外和体内疗效,以降低血糖和减肥.
主要方法:
- 合成8种三重受体激动剂和16种与脂肪酸修饰的结合物.
- 通过高分辨率质谱和映射来确认化学结构.
- 在体外和体内生物效应的评估,包括结构-活性关系 (SAR) 分析和分子对接.
主要成果:
- 化合物TRA24在体外和体内表现出极好的疗效.
- 在正常和db/db小鼠模型中,TRA24在体内表现出高于tirzepatide的疗效.
- 分子对接揭示了GLP-1R.中TRA22偏向激动的结构基础.
结论:
- 一种新型的三重受体激动剂,TRA24,被确定为治疗代谢障碍的有希望的化合物.
- TRA24显示出可能比现有疗法更有效地降低血糖和减肥的潜力.
- 了解偏见激励的结构基础可以指导未来的药物设计.
相关概念视频
Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.2K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.2K
G Protein-coupled Receptors
13.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.5K
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
654
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
654


